![Tomer Yossef](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tomer Yossef
Geen lopende functies
Loopbaan van Tomer Yossef
Eerdere bekende functies van Tomer Yossef
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Directeur/Bestuurslid | 31-07-2018 | - |
Independent Dir/Board Member | 31-07-2018 | - |
Opleiding van Tomer Yossef
Tel-Aviv University | Graduate Degree |
Statistieken
Internationaal
Israël | 3 |
Operationeel
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Graduate Degree | 1 |
Sectoraal
Health Technology | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Beurs
- Insiders
- Tomer Yossef
- Ervaring